Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222273 · ClinicalTrials.gov registry record · NA
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01222273 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 7 participants.
The verdict
NCT01222273, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.
Interventions
- DIETARY_SUPPLEMENT cholecalciferol (Vitamin D3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222273
The ClinicalTrials.gov registry entry for NCT01222273 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cholecalciferol (Vitamin D3) is the first listed.
NCT01222273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222273 about?
NCT01222273 is a clinical study titled "Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis". The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.
What is the current status of trial NCT01222273?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2010-09. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01222273?
The interventions under investigation include: cholecalciferol (Vitamin D3) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01222273?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.